Inhibrx Biosciences Inc. (INBX) — Financial statements
Income statement, balance sheet, and cash flow for Inhibrx Biosciences Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1↑550.0% | 0.20↓88.9% | 2↓17.9% | 2↓69.2% | 7 | |
| Cost of Revenue | 2↑8.7% | 2↑91.9% | 1↓98.9% | 110↑3999.2% | 3 | |
| Gross Profit | -1↑43.3% | -2↓442.4% | 0.61↑100.6% | -108↓2533.9% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 113↓44.5% | 204↑6.9% | 191↑73.0% | 110↑54.2% | 71 | |
| General & Administrative Expenses | 23↓81.8% | 128↑335.3% | 29↑39.1% | 21↑71.0% | 12 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 23↓81.8% | 128↑335.3% | 29↑39.1% | 21↑71.0% | 12 | |
| Other Expenses | -2↓8.7% | -2↓1048.2% | -0.20↑99.8% | -110↓54.2% | -71 | |
| Operating Expenses | 134↓59.4% | 329↑49.8% | 220↑940.8% | 21↑71.2% | 12 | |
| Total Costs & Expenses | 136↓58.9% | 332↑50.1% | 221↑68.3% | 131↑56.9% | 84 | |
| Operating Results | ||||||
| Operating Income | -135↑59.3% | -331↓51.2% | -219↓69.8% | -129↓68.6% | -77 | |
| Depreciation & Amortization | 2↑8.7% | 2↑91.9% | 1↓2.8% | 1↑2.5% | 1 | |
| EBITDA | -133↓107.8% | 1,703↑924.1% | -207↓64.3% | -126↓66.9% | -75 | |
| EBIT | -135↓107.9% | 1,701↑918.3% | -208↓63.6% | -127↓65.9% | -77 | |
| Interest & Other Income | ||||||
| Net Interest Income | -5↓82.2% | -3↑87.2% | -20 | 0.00 | 0.00 | |
| Interest Income | 8↓31.0% | 11↓8.2% | 12↓26.0% | 16↑208.8% | 5 | |
| Interest Expense | 12↓9.6% | 13↓57.6% | 32↑97.7% | 16↑208.8% | 5 | |
| Non-Operating Income | 0.00↑100.0% | -2,033↓17828.1% | -11↓446.4% | -2↓14721.4% | -0.01 | |
| Other Income / Expenses | -5↓100.2% | 2,019↑9947.4% | -21↓27.3% | -16↓209.6% | -5 | |
| Income Before Tax | -140↓108.3% | 1,688↑804.0% | -240↓65.1% | -145↓77.6% | -82 | |
| Income Tax Expense | 0.00↑0.0% | 0.00↓33.3% | 0.00↑0.0% | 0.00↑50.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -140↓108.3% | 1,688↑804.0% | -240↓65.1% | -145↓77.6% | -82 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -140↓108.3% | 1,688↑799.2% | -241↓66.2% | -145↓77.6% | -82 | |
| Bottom-Line Net Income | -140↓108.3% | 1,688↑799.2% | -241↓66.2% | -145↓77.6% | -82 | |
| EPS (Basic) | -9.04↓107.8% | 116.58↑2377.0% | -5.12↓41.4% | -3.62↓68.4% | -2.15 | |
| EPS (Diluted) | -9.04↓107.8% | 116.58↑2377.0% | -5.12↓41.4% | -3.62↓68.4% | -2.15 | |
| Weighted Average Shares | 15↑7.0% | 14↓69.3% | 47↑17.5% | 40↑5.5% | 38 | |
| Weighted Average Diluted Shares | 15↑7.0% | 14↓69.3% | 47↑17.5% | 40↑5.5% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.